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ABSTRACT
FOXA1 is a transcription factor capable to bind si-
lenced chromatin to direct context-dependent cell
fate conversion. Here, we demonstrate that a com-
pact palindromic DNA element (termed ‘DIV’ for its
diverging half-sites) induces the homodimerization
of FOXA1 with strongly positive cooperativity. Al-
ternative structural models are consistent with ei-
ther an indirect DNA-mediated cooperativity or a di-
rect protein-protein interaction. The cooperative ho-
modimer formation is strictly constrained by pre-
cise half-site spacing. Re-analysis of chromatin im-
munoprecipitation sequencing data indicates that
the DIV is effectively targeted by FOXA1 in the
context of chromatin. Reporter assays show that
FOXA1-dependent transcriptional activity declines
when homodimeric binding is disrupted. In response
to phosphatidylinositol-3 kinase inhibition DIV sites
pre-bound by FOXA1 such as at the PVT1/MYC locus
exhibit a strong increase in accessibility suggest-
ing a role of the DIV configuration in the chromatin
closed-open dynamics. Moreover, several disease-
associated single nucleotide polymorphisms map to
DIV elements and show allelic differences in FOXA1
homodimerization, reporter gene expression and are
annotated as quantitative trait loci. This includes the
rs541455835 variant at the MAPT locus encoding the
Tau protein associated with Parkinson’s disease. Col-
lectively, the DIV guides chromatin engagement and
regulation by FOXA1 and its perturbation could be
linked to disease etiologies.
INTRODUCTION
Themechanism by which transcription factor (TF) proteins
scan the genome to arrive at functional target sites and to
direct changes in chromatin architecture and gene expres-
sion programs that confer cellular identities is only poorly
understood. Puzzlingly, individual TFs bind only a small
subset of their high-affinity consensus sites encoded in the
genome. Dimeric TF partnerships can direct site selections
and increase specificity by favoring some genomic locations
over others. The forkhead box A1 (FOXA1) protein belongs
to a class of TFs capable to engage their cognate binding
sites even in the context of compacted chromatin, which is
not accessible to most other TFs (1–4). This way, FOXA1
does so-called ‘pioneering’ work necessary to direct cellu-
lar differentiation during organ development (reviewed in
(5)), during cell fate programming in vitro (6,7) as well as
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during pathological reprogramming events such as onco-
genic transformation (8,9). In mammals, FOXA1 directs
liver development and metabolism (10–12), and has impor-
tant functions in other endodermally derived organs (re-
viewed in (13)). In breast and prostate epithelia, FOXA1
recruits and collaborates with nuclear hormone receptors,
especially estrogen receptor (ER) (14–16) and androgen re-
ceptor (AR) by enabling them to access sites they could oth-
erwise not target (17,18). FOXA1 has so far been thought to
bind chromatin either as monomer or as heterodimer with
nuclear receptors. Whilst it is clear that FOXA1 plays fun-
damental roles in oncogenesis and development, themecha-
nism of how FOXA1 engages chromatin to orchestrate reg-
ulatory programs and the sequence-function relationships
enabling its pioneering function are not resolved (19,20).
FOXA1 possesses an ∼100 amino acid forkhead box
DNA binding domain (DBD) named after the homologous
Drosophila gene fkh (forkhead) (11,21). The forkhead DBD
was likened to a butterfly with a core consisting of three
-helices and two extended ‘wings’ forming a ‘winged he-
lix’ structure (22). Interestingly, this structure resembles the
fold of the linker histones H1/H5, whose role is to compact
nucleosomes into higher order structures by binding to the
dyad axis of the histone octamer (22,23). The chromatin
loosening activity of FOXA1 has been attributed to this
similarity and it was suggested that FOXA1 de-compacts
nucleosomal arrays by directly competing with linker his-
tones H1 (1). A direct interaction of a C-terminal sequence
motif of FOXA1with the nucleosome core particle was also
found to be important for this activity (1). Yet, as a number
of structurally unrelated TFs were also reported to be able
to bind nucleosomes in vitro, the similarity to H1 does not
appear to be an essential feature of pioneer TFs (24).
FOXA1 binds as monomer to an AWTRTTKRYTY
(whereW:A/T,K:G/T,R: A/GandY: C/T) consensus site
(25) and several disease-associated single nucleotide poly-
morphisms (SNPs) were identified to map to this consensus
and influence its binding affinity (26,27). This suggests that
even a subtle perturbation to the cistrome of FOXA1 could
contribute to disease progression. We have recently devel-
oped a new co-motif discovery algorithm termed TACO
(Transcription factor Association from Complex Overrep-
resentation) that enables the discovery of cell-type specific
TF dimer candidates from deep sequencing data even for
overlapping position weight matrices (PWMs) (28,29). Us-
ing TACO, we found a strong enrichment of two palin-
dromic FOXA1 motifs in DNase I hypersensitivity regions
specific for breast and prostate cancer cells (29). In one
motif the FOXA1 half-sites are arranged in a convergent
orientation and were therefore termed ‘CON’ and in the
second motif the half-sites are arranged in a compact di-
verging orientation and termed ‘DIV’ (Figure 1A). Subse-
quently, composite DNA elements resembling both CON
as well as DIV motifs were recovered in ChIP-exonuclease
sequencing data (30,31) as well as in high-throughput SE-
LEX studies (32,33). These findings implied that FOXA1
and other forkhead factors often target genomic DNA as
homodimers. TF homodimerization can profoundly influ-
ence the selection of target genes and increase binding affin-
ity in particular by decreasing the dissociation rate (34).
Moreover, changes in the quaternary structure of TF/DNA
complexes can enable different outcomes regulated by one
and the same TF in alternative genomic contexts. This has,
for example, been demonstrated for Pit1-Oct-Unc (POU)
TFs that recruit different co-factors depending on theDNA
induced dimeric conformations (35–37). This way, a TF
can act as repressor in the context of one dimeric confor-
mation and as an activator in another. We therefore de-
cided to study the novel FOXA1 dimer configuration using
structural modeling, quantitative dimer assays, interroga-
tion of genomic datasets and two types of reporter assays.
We show that DIV DNA directs FOXA1 homodimeriza-
tion in a highly cooperative fashion with strict constraints
on half-site spacing. Structural models based on a crystal
structure of FOXA3 bound to a non-canonical DNA el-
ement suggest that major structural adjustment would be
required to enable direct interactions between juxtaposed
FOXA1 molecules. FOXA1/DIV homodimer sites control
chromatin binding, nucleosome dynamics and gene expres-
sion at critical FOXA1-dependent enhancers. Intriguingly,
disease-associated SNPs disrupt or repress FOXA1 homod-
imerization and the comparison of dimer promoting versus
dimer impeding alleles reveals differential regulatory activ-
ities.
MATERIALS AND METHODS
Purification of the FOXA1 DNA binding domain (DBD)
Protein production was performed using protocols es-
tablished at the protein production platform (PPP) of
the NTU, Singapore (https://www.proteins.sg/). Briefly,
a pNic28-Bsa4 expression plasmid encoding the human
FOXA1 DBD (spanning Asp158-Pro272 corresponding to
24.4% of the 472 amino acid full length protein; Gen-
Bank accession BC033890) was transformed into Rosetta
(DE3) BL21 competent cells (Novagen) and grown in
terrific broth (TB) medium at 37◦C to an OD600 0.6–
0.8. Protein expression was induced with 0.2 mM iso-
propyl -D-1-thiogalactopyranoside (IPTG) for 12 h at
25◦C. After harvesting by centrifugation (8000 rpm for
15 min at 4◦C), the bacteria were lysed by superson-
ication (400 W, 5 s for 99 times with 8 s gap be-
tween each time) in lysis buffer (100 mM HEPES ((4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 500mM
NaCl, 10 mM imidazole, 10% glycerol, 0.5 mM TCEP
(tris(2-carboxyethyl)phosphine) and 100 M PMSF). The
lysate was centrifuged again (10 000 rpm for 30 min at
4◦C) to pellet the cellular debris while the supernatant was
loaded onto a column containing Ni-NTA agarose beads
(Thermo Fisher) equilibrated in lysis buffer. After wash-
ing with Buffer A (20 mM HEPES, 500 mM NaCl, 10 mM
Imidazole, 10% glycerol and 0.5 mM TCEP, pH 7.5) and
buffer B (20 mM HEPES, 500 mM NaCl, 25 mM imida-
zole, 10% glycerol and 0.5 mM TCEP, pH 7.5) for 5 times
each, the target protein was eluted with elution buffer (20
mMHEPES, 500 mMNaCl, 500 mM imidazole, 10% glyc-
erol and 0.5 mMTCEP, pH 7.5). Some batches were further
purified by size exclusion chromatography using the AKTA
express system and a Superdex 75 column (GEHealthcare).
FOXA1 DBD alanine 232 mutations were introduced by
PCR with Phusion polymerase (Thermo Fisher) using the
circular pNic28-Bsa4 vector as template followed by DpnI
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digestion and verified by Sanger sequencing. Proteins were
purified following the same procedures.
Purification of full length FoxA1 protein
Full-length mouse FoxA1 protein (NM 008259.3) was
cloned into a pET-28A vector containing aN-terminal His6
tag followed by a thrombin cleavage site (IGE, www.igebio.
com). The protein expression was induced in Rosetta DE3
cells grown in Luria broth (LB) medium by adding 0.2 mM
of IPTG. After 4 h, cells were harvested by centrifugation
and resuspended in lysis buffer (5 mM imidazole, 20 mM
Tris–HCl pH 7.9, 500 mM NaCl, 20 mM PMSF and 8 M
urea) followed by 99 sonication cycles at 400 W for 5 s with
8 s breaks on ice. The lysate was centrifuged at 12 000 rpm
for 30 min and the supernatant was incubated with 1 ml of
Ni-NTA agarose beads (Thermo Fisher) and washed thor-
oughly. The protein was first eluted with elution buffer (400
mM Imidazole, 20 mM Tris, pH 7.9, 500 mM NaCl and
8M urea) and subjected to a step-wise refolding procedure
by dialysis in the cold room: 6 M urea buffer (20 mM Tris
pH 7.9, 500mMNaCl and 6Murea) for 1h, 4M urea buffer
(20 mM Tris pH 7.9, 500 mM NaCl and 4 M urea) for 2 h,
2 M urea buffer (20 mM Tris pH 7.9, 500 mM NaCl and 2
M urea) for 2 h, urea-free buffer (20 mM Tris pH 7.9, 500
mM NaCl) for 2h and collected in storage buffer (20 mM
Tris pH 7.9, 100 mM NaCl).
EMSA (electrophoretic mobility shift assays)
5′ Cy5-labeled forward strand DNA oligo and their re-
verse complementary unlabeled strand (HPLC-purified,
purchased from Invitrogen or BGI) were first annealed in
1× annealing buffer (20 mM Tris–HCl, pH 8.0; 50 mM
MgCl2; 50 mM KCl) in a PCR block (Bio-rad) by heat-
ing to 95◦C for 5 min and gradual cooling at 1◦C/min to
16◦C. 1-100 nMof dsDNAwas incubated with varying con-
centrations of the FOXA1 DBD or of mouse FoxA1 full
length (FoxA1 FL) protein in 1X binding buffer (20 mM
Tris-HCl, pH 8.0; 0.1 mg/ml bovine serum albumin; 50μM
ZnCl2; 100 mMKCl; 10% (v/v) glycerol; 0.1% (v/v) Igepal
CA630 and 2 mM -mercaptoethanol) for 1 h at 4◦C and
10 l of sample was loaded onto pre-run 12% native poly-
acrylamide mini-gels (for FoxA1 FL 6% gels were used) in
1× Tris–glycine buffer (0.025 M Tris, 0.192 M glycine, pH
8.0) and electrophoresed for 30 min at 200 V in the cold
room. The bands were detected with a Fuji FL-7000 scan-
ner (GEHealthcare) using 635/670 nm excitation/emission
wavelengths and band intensities were quantified using the
ImageQuantTL software. Cooperativity factors were calcu-
lated as previously described (34,38,39). Dissociation con-
stants (Kd) from titration experiments with 1 nM DNA
probe were estimated using non-linear curve fitting in R
treating the DNA as fixed parameter as previously de-
scribed (38). Sequences of all tested DNA elements are
listed in Supplementary Table S1.
Vector construction
For luciferase vector construction, 500 bp DNA fragments
with central DIV motif candidates were cloned into a
pGL4-TK luciferase reporter plasmid (Promega, E2241)
using Phusion DNA polymerase (Thermo Fisher) or KOD-
Fx-neo DNA polymerase (Toyobo). Restriction enzymes
KpnI (NEB) and EcoRV (NEB) were used to digest the
PCR products and the pGL4-TK backbone. Digested se-
quences were gel purified (Tiangen) and ligated using the
T4 ligase (Takara). For constructing the Tol2 reporter vec-
tor (40), DIV motif candidates were digested with KpnI or
BglII (NEB, forward sequence) and XhoI (NEB, reverse se-
quence) and then ligated. Full length human FOXA1 (gene
ID: 3169) was PCRamplified using primers listed in Supple-
mentary Table S1 and cloned into the pcDNA3 (41) vector
using restriction enzymes EcoRI (NEB) and XhoI (NEB).
Site-directed mutagenesis was carried out by amplifying the
target plasmid with Phusion polymerase (Thermo Fisher)
using overlapping primers encoding the mutated sequence
followed by Dpn I (NEB) digestion. All DNA oligos are
listed in Supplementary Table S1.
Tol2 reporter assay (endogenous FOXA1 reporter assay)
MCF7 cells (ATCC) were grown in Dulbecco’s Modified
Eagle Medium (DMEM, Gibco) with 10% fetal bovine
serum (FBS, Biowest) in 24-well plates to 50% confluency.
Cells were transfected using 0.8 l X-tremeGENE 9 DNA
transfection reagent (Roche) containing 500 ng of Tol2GFP
reporter plasmid and 500 ng pCAGGS-TP Transposase ex-
pressing plasmid (40). After 72 h incubation, cells were
trypsinized using 200 l 0.25% Trypsin (Gibco), washed
twice with 500 l Dulbecco’s Phosphate Buffered Saline
(DPBS, Gibco) and resuspended in 500 l DPBS. GFP
fluorosecences was measured using Fluorescence-Activated
Cell Sorting (FACS) method with a Calibur Flow Cytome-
ter (BD Bioscience) using the GFP channel after gating
for 10,000 living cells. Total GFP expression level of each
tested sample was evaluated using the FlowJo software
(FlowJo™). First, the median GFP signal of all 10 000 cells
was recorded. Next, the percentage of GFP positive cells
was determined after calibrating the gating using a Tol2 vec-
tor control without enhancer insert. The final expression
value was calculated by multiplying median GFP expres-
sion with the fraction of GFP positive cells.
Luciferase assay
Around 104 HCT116 cells (ATCC) were plated in modi-
fied McCoy’s 5A medium (Gibco) supplemented with 10%
FBS (Biowest) in 24-well plates. Alternatively, 105 T47D
cells (ATCC) were plated in one well of 24-well plate in
RPMI Media 1640 (Gibco). Both cell lines were grown
for 24 h to reach 80% confluency. 200 ng luciferase re-
porter plasmids, 1 ng pRL-SV40 Renilla (E2231, Promega)
and 50 ng pcDNA3-FOXA1 were mixed with 0.8 l of
X-tremeGENE 9 DNA Transfection Reagent (Roche) per
well. After 24 h growth at 37◦C and 5%CO2, cells were care-
fully washed with 500 l (DPBS) and lysed with 100 l 1×
Passive Lysis Buffer (Promega). Dual Luciferase Reporter
System (Promega) and a Veritas Microplate Luminometer
(Turner Biosystems) were used to measure the Luciferase
and Renilla activity following the manufacturer’s instruc-
tions.
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Bioinformatics analysis
ChIP-seq data were downloaded from ENCODE
(https://www.encodeproject.org) in narrowPeak for-
mat or from the Cistrome project (http://cistrome.org/
Cistrome/Cistrome Project.html). A subset of the datasets
was re-processed using raw reads downloaded from the
GEO followed by genome alignment with bowtie2 (42) and
MACS for peak calling (43) with default parameters. Col-
umn 7 (signalValue) of the ENCODE narrow peak format
was used as peak score in the boxplots. Accession numbers
of data used in this study are listed in Supplementary Table
S1. FOXA1DIV (D) motif models are generated with com-
posite TRANSFAC motifs M00791 and M01012 with the
latter displaced with 4 bp offset using previously published
data (29). Genome-wide motif coordinates were identified
at a motif score threshold that provided 80% sensitivity
in detecting ChIP-seq peaks. For the control motif coor-
dinates (CON, C), spacers from +1 bp to +10 bp between
two overlapped monomer motifs were added. Moreover,
we excluded control loci that would overlap a ‘correctly
spaced’ DIV dimer locus. As for the CON motif, we used
the TRANSFACmotif M0102 twice, with the second motif
reverse complemented and displaced by 9 bp. To obtain
genome-wide coordinates for monomer locations we used
FOXA1 monomer motif PWM provided by the HOMER
database (AAAGTAAACA, discovered in a FOXA1
ChIP-seq study in MCF7 cells GEO accession GSE26831)
and used the HOMER scanMotifGenomeWide.pl function
with the hg38 genome.
Intersections between ChIP-seq peaks and mo-
tif coordinates were done using bedtools (http:
//bedtools.readthedocs.io/en/latest/, (44)) functions in-
tersectBed or windowBed (window 100 bp) or foverlaps
of the data.table package (https://cran.r-project.org/web/
packages/data.table/). ATAC-seq data were downloaded
(GEO accession number GSE84515) and converted into
fastq using fastq-dump. Bowtie2 was used to align the reads
to the hg38 genome build followed by further processing
and file format conversions using samtools. These files were
used for coverage analysis over ChIPseq peak categories
defined by matches to FOXA1 motif types. EAseq v.1.04
(45) was used to draw ATAC-seq and ChIP-seq read
coverage heat maps normalized by reads-per-million. R
packages data.table and ggplot2 where used for analysis
and visualization using custom scripts.
Modeling of FOXA1 dimer structures
Models of FOXA1 homodimers on DIV DNA with 0
to 10 bp spacer were prepared by using a crystal struc-
ture of a HNF-3 (FOXA3) forkhead/DNA complex
(protein data bank (PDB) accession: 1VTN) (22). The
amino acid sequence of the FOXA3 portion present in
the crystal structure is 96% identical with the human
FOXA1 DNA binding domain (UNIPROT ID: P55317).
The DNA sequence bound to FOXA3 in the crystal struc-
ture is 5′-G1G2T3T4G5-3′/3′-C’1C’2A’3A’4C’5-5′, which de-
viates from the FOXA1 consensus 5′-T1A2T3T4T5-3′/3′-
A’1T’2A’3A’4A’5-5′. We used the conserved binding of
Asn165 with A’4 via a bi-dentate H-bond as quality con-
trol criterion to validate our dimer models and also to con-
struct alternative models with switched contacts. The strat-
egy to model FOXA1 dimers on differently spaced elements
orwith switchedAsn165-Adenine contacts on theDIV (D0)
element is graphically explained in Supplementary Figure
S1A.
First, binary FOXA1/DNA complexes were prepared
by comparative homology modeling (https://www.salilab.
org/modeller) using the template of the FOXA3 crystal
structure. The DNA element was considered as rigid body
during homology modeling. Next, we designed DNA el-
ements with canonical B-DNA geometry containing half
sites matching the sequences in 1VTN to facilitate super-
position of the binary FOXA1/DNA on forward and re-
verse strands of the ideal B-DNA. The sequence CAACwas
used for superposition to obtain the initial FOXA1 dimer
models and adjacent bases were concatenated. Next, nu-
cleotides of the DIV from the PVT1 enhancers were used
to replace nucleotides of the initial models to construct a
model with a consensusDIV sequence (Supplementary Fig-
ure S1B and C). The energy of the ternary complex mod-
els was minimized by using amber force fields ff14SB for
the proteins (46) and amber force fields FF99BSC0 (47) for
DNA with the bidentate Asn165––adenine hydrogen bond
defined as positional restraint. Superposition models were
prepared by VMD and figures were generated using both
Chimera 1.11 (48) (https://www.cgl.ucsf.edu/chimera/) and
VMD1.9.3 (https://www-s.ks.uiuc.edu/Research/vmd/vmd-
1.9.3/).
RESULTS
FOXA1 forms a highly cooperative homodimer on a compact
DNA element
By scoring for the enrichment of co-occurring position
weight matrices in cell-type-specific DNase hypersensitive
(HS) regions in 78 human cell lines, we previously identified
candidate TF dimer configurations that could contribute to
their cell-type specific functions (28,29). Two palindromic
FOXA1 motifs constituted top hits of this analysis. First,
a compact composite motif termed ‘diverging’ DIV (D0)
motif was found where the AT-rich core of the forkhead
motif (TATTT) overlap so that the central TA dinucleotide
is shared by juxtaposed half-sites (AAATATTT). We also
identified a less compact compositemotif with forkheadmo-
tifs arranged in alternative directions which we called ‘con-
verging’ or CON (C0)motif (Figure 1A).Wewere interested
in both motifs for their strong enrichment in the breast can-
cer cell line MCF7 and prostate cancer cell line LNCaP.
To test whether FOXA1 homodimerises on these se-
quences, we established quantitative electrophoretic mobil-
ity shift assays (EMSAs) using the purified DNA binding
domain (DBD) of FOXA1 (henceforth termed FOXA1). In
the absence of DNA, FOXA1 does not dimerize but forms
a monodisperse monomer as judged from calibrated size-
exclusion chromatograms (SupplementaryFigure S1D).We
first performed EMSAs with 1 nM DNA probe encoding
the FOXA1 monomer element and a concentration series
of FOXA and measured a mean Kd monomer of 2.4 ± 1.06
nM (n = 3, Figure 1B). Similar titrations in the presence
of DIV DNA showed that dimeric FOXA1 bands begin
to form at the lowest FOXA1 concentrations (0.61 nM)
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Figure 1. FOXA1 cooperates on the DIV motif with strict constraints on half-site spacing. (A) Sequence logos representing position weight matrices
(PWMs) of the FOXA1 monomer motif as well as logos for the composite DIV (D0) and CON (C0) motifs. The source PWMs are in Supplementary
Table S1. (B, C) EMSAs using 1 nM DNA probes with a monomeric FOXA1 element (B) or the composite DIV element (C) and a concentration series
of the FOXA1 DBD. Lanes 1–14 are marked and contain decreasing FOXA1 DBD concentrations. 1: 2500 nM; 2: 1250 nM; 3: 625 nM; 4: 312.5 nM; 5:
156.3 nM; 6: 78.1 nM; 7: 39 nM; 8: 19.5 nM; 9: 9.8 nM; 10: 4.9 nM; 11: 2.4 nM; 12: 1.2 nM; 13: 0.6 nM and 14: no protein). DNA sequences are shown
with core binding sites colored red. Dimer (D), monomer (M) and free DNA bands (F) are indicated. (D) EMSAs using DNA probes with DIV and CON
motifs and mutants with inserted spacers (D2, C1 and C−1). 100 nM of each Cy5-labelled double stranded DNA was incubated with 400 or 320 nM of
the FOXA1 DBD protein. (E) EMSAs using 100 nM DIV DNA (D0) and 1 to 10 base-pair spacers (D1 to D10) performed with 400 nM FOXA1 DBD
protein. (F) Cooperativity values () calculated after quantifying dimer, monomer and free DNA fractions from EMSAs (38,39). The mean ± SD of at
least five measurements is shown (raw values in Supplementary Table S1).
indicating a dimerization with strongly positive coopera-
tivity (Figure 1C). An apparent binding affinity Kd app for
the binding of FOXA1 to DIV DNA was determined to
be 4.5 ± 1.6 nM by regarding monomeric and dimeric
states as an overall bound DNA fraction. To quantify the
efficiency of the FOXA1 to homodimerize, we next esti-
mated the cooperativity factor () under equilibrium con-
ditions at a DNA concentration of 100 nM. These measure-
ments provide ratios of equilibrium binding constants (=
Kd monomer/Kd dimer). Here, Kd dimer represents the dissocia-
tion constant for the binding of a second FOXA1 molecule
to a pre-formed FOXA1/DNA complex. Thus, cooperativ-
ity factors indicate how two TF molecules influence their
mutual occupancies on a given DNA element with com-
posite binding sites (34,38). If  > 1, TFs bind with pos-
itive cooperativity; if <1, TFs bind with negative coop-
erativity or, in other words, compete and if  = 1 binding
is independent or non-cooperative (49). Using these assays,
we compared the binding of FOXA1 to co-motifs enriched
in DNase-HS regions (D0/DIV and C0/CONmotifs) with
control elements where the spacing between half-sites was
altered (D2, C1 and C-1). FOXA1 binds DIV DNA with
highly positive cooperativity ( = 56.3 ± 11.9; Figure 1D-
F, Supplementary Figure S1E, Supplementary Table S1).
For the C0 DNA a profoundly lower cooperativity factor
was measured ( = 1.8 ± 1.3). If the half-site spacing is
perturbed, the dimerization is impeded for both configura-
tions of DNA elements. To further dissect the reliance of
cooperative binding on half-site spacing, we inserted spac-
ers from 1 to 10 bp between the half sites of the DIV (Figure
1E and F, Supplementary Figure S1F, Supplementary Table
S1). This experiment revealed that cooperative dimerization
of FOXA1 on DNA strictly depends on compact half-site
spacing. Addition of spacers separating the FOXA1 core
motifs decreased  by at least an order of magnitude and in
the case of the D3 configuration completely obliterated the
formation of dimeric complexes.While the forkheadDBD is
sufficient for cooperative dimerization, this binding mode is
also retained in the context of recombinantly purified full-
length mouse FoxA1 protein (Supplementary Figure S1G).
Structural modeling suggests alternative mechanisms for the
dimer formation
To understand the basis for FOXA1 dimerization on DIV
DNA, we constructed a series of FOXA1DBD dimer mod-
els. First, we used a published FOXA3 DBD-DNA crys-
tal structure (PDB ID 1VTN (22)) to produce FOXA1 ho-
mology models. The FOXA3 DBD spans about 25% of the
full-length protein and differs by five amino acids from the
FOXA1 DBD. Next, dimer models were generated by the
superposition of two binary FOXA1/DNA models onto
ideal B-DNA templates containing DIV sequences (Sup-
plementary Figure S1A-C). To maintain the experimental
DNA curvature, we concatenated experimental DNA frag-
ments followed by removal of the B-DNA template. Finally,
the complex models were energy minimized allowing for
structural adjustments of both the protein and the DNA
components leading to models with curved DNA. Notably,
the DNA element of the 1VTN (CGTTG) model differs at
several key positions from the forkhead consensus (TATTT)
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/46/11/5470/4970502 by U
niversity of H
ong Kong Libraries user on 14 D
ecem
ber 2018
Nucleic Acids Research, 2018, Vol. 46, No. 11 5475
Figure 2. Structural model of dimeric FOXA1/DNA complexes. Structural models were constructed using FOXA1 homology models generated using
the FOXA3/DNA crystal structures (PDB ID 1VTN) as template. The modeling strategy is outlined in Supplementary Figure S1A–C. The interaction
of Asn165 with an Adenine is a critical mediator of the DNA recognition of forkhead DBDs. Based on the alignment with binary forkhead DBD/DNA
structures Asn165 is expected to interact with A4’ in both 5′-T1A2T3T4T5-3′/3′-A’1T’2A’3A’4A’5-5′ DIV half sites (A, D0 M1). We surmised that in the
context of a homodimeric complex Asn165 could switch Adenines leading to alternative models where Asn165 contacts A5’ (B, model D0 M4) or A3’ (C,
model D0 M7). Left panels show overviews and right panels are zoomed in views highlighting amino acids V229 and A232 exposed to the neighboring
molecule that could mediate the dimer formation. The DNA is shown as gray tube, protein helices, sheets or loops are in red, blue and yellow cartoons,
respectively. The molecular surface is shown in transparent green. Selected amino acids are labeled and shown as ball-and-sticks. The DNA sequence used
to construct the models is shown and nucleotides (or their reverse-complement) contacted by Asn165 are in red.
(Supplementary Figure S1B). Therefore, the curvature of
the DNA of a binary complex with FOXA1 may not be
correctly represented in presently available models. Further,
profound structural changes of the DNA could accompany
the assembly of dimeric complexes.
A conserved feature in forkhead DBD/DNA complexes
is a bidentate hydrogen bound of Asn165 with Adenine
A’4 (5′-T1A2T3T4T5-3′/3′-A’1T’2A’3A’4A’5-5′) (Supplemen-
tary Figure S1A). We first performed superpositions that
maintain the interaction of Asn165 with A’4 in the final
complex models. In these models we could not observe any
intermolecular protein-protein interactions between juxta-
posed FOXA1 molecules suggesting that the dimer forma-
tion could be facilitated allosterically throughDNA (Figure
2A). However, as theDIV is AT-rich we surmised that in the
context of a dimeric complex Asn165 could be induced to
switch Adenines and bind to A’3 or A’5 instead. To test this
possibility, we constructed nine alternative models with all
possible combinations of Asn165 with Adenines 3–5 in ei-
ther half site (Supplementary Figure S1A, B). Out of the
nine models three are symmetric, that is, Asn165 binds the
same Adenine in either of the two half-sites (Figure 2A–
C). Out of the three symmetric models for FOXA1 homod-
imer, the D0-M4 model (where Asn165 binds A’5) shows
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and extensive hydrophobic protein-protein contact inter-
face formed predominantly by Val229 and Ala232 (Fig-
ure 2B and Supplementary Figure S1C). We also gener-
ated structure models for all DIV control motif configura-
tions with spacer lengths 1–10 (Supplementary Figure S2A,
B). In this set of models, severe clashes were observed for
the D3 configuration (Supplementary Figure S2B) consis-
tent with the absence of any dimer band in EMSAs (Figure
1E). Remaining configurations showed moderate structural
clashes, which could possibly be relieved by conformational
adjustments of the protein and changed shape of the DNA
(Supplementary Figure S2A).
The D0-M4 model (Figure 2B) appears similar to the
non-cooperative D2 model that was generated by sepa-
rating the otherwise overlapping FOXA1 half-sites of the
DIV (Supplementary Figure S2A). However, a superposi-
tion between the 2 models reveals that the beta-sheets of
the FOXA1 monomers are closer to each other in the D2
model, potentially leading to a suboptimal interaction inter-
face. Moreover, the DNA sequence differs between the two
models, leading to alternative DNA shapes that may cause
modifications of the predicted protein–protein interaction
interface (Supplementary Figure S2A). Thus, the D0 M4
model cannot be invalidated due to the lack of positive
cooperativity on the D2 element (Figure 1D-F). We pro-
pose that D0 M1, D0 M4 and D0 M7 all represent po-
tentially valid initial models for the FOXA1 dimerization
on the DIV motif based on the currently available data.
Notably, only the D0 M1 model has the direct readout of
the DNA sequence similar to that observed for the consen-
sus sequence. Further validation of the models with experi-
ments and molecular dynamics simulation is needed.
Notably, an Ala232Val mutation has been reported to
drive prostate cancer (50).We decided to test whether muta-
tions to residue Ala232 influence cooperative dimerization
on the DNA. However, mutations associated with prostate
cancer and 10 other substitutions only mildly influence the
cooperativity on the DIV sequence (<1.5-fold change to
, Supplementary Figure S2C). As a more rigorous test
we also constructed double mutants where both of the pu-
tative interface residues Val229 and Ala232 were concur-
rentlymutated to acidic glutamates (Val229Glu/Ala232Glu
and Val229Arg/Ala232Arg). EMSAs showed that the
Val229Arg/Ala232Arg double mutation does not influence
DNA binding (Supplementary Figure S2D). However, sur-
prisingly, the Val229Glu/Ala232Glu double mutations lead
to amarked increase in the cooperativity although the affin-
ity for monomeric binding is reduced.
In the absence of experimental structures of a ternary
FOXA1/DIV complex, the curvature of the bound DNA,
the protein-DNA contact interface and the structural basis
for dimerization remains hypothetical. The mechanism for
the cooperative dimer formation could be due to two basic
mechanisms. First, direct protein-protein interactions that
would require major structural adjustments and including
contact interface switching or the deformation of DNA.
Second, DNA-mediated allosteric mechanism could facili-
tate cooperative DNA recognition by FOXA1. Such mech-
anisms have been described for a growing number of TF
dimer pairs and appear to be common theme in TF biology
(51–53).
FOXA1 strongly binds to DIV loci in human cancer cells
FOXA1 is a master regulator of endodermal cell and tis-
sue types but also associated with tumorigenesis in several
cancers including breast, prostate and liver cancer ((9), re-
viewed in (8)). Accordingly, FOXA1 expression is highest
in normal liver and intestine epithelium as well as breast,
prostate, gastrointestinal and liver cancer cell lines amongst
a panel of 562 samples analyzed by the FANTOM5 consor-
tium (54) (Figure 3A). To study the relevance of the DIV to
define the genomic binding profiles of FOXA1, we next de-
fined four categories of binding locations in publicly avail-
able ChIP-seq datasets (Figure 3B). Category ‘D’ contains
sites with matches to the DIV PWMs in the peak region
(1.1e+5 instances in the human genome hg38, ‘D’). Cate-
gory ‘C’ are control dimer sites that have matches to mo-
tifs where the dimer promoting configuration is disrupted
by introduction of 1–10 spacers (D1-D10, 5.1e+5 loci in
hg38, Supplementary Figure S3A). Category ‘C’ controls
for the preference for a specific configuration but maintains
the number of half sites similar to DIV locations. Next,
we defined locations where FOXA1 binds exclusively as
monomer (‘M’). Lastly, remaining locations are designated
‘N’ for ‘no motif ’ for the lack obvious matches to any of the
three types of FOXA1 motifs (Figure 3B). FOXA1 ChIP-
seq datasets from MCF7, T47D and HepG2 cells typically
contain 1000–2000matches to theDIV and show an enrich-
ment for the DIV as compared to the dimer control with re-
spect to the genome-wide DIV/control ratio (Supplemen-
tary Figure S3B). As a proxy for cooperative dimerization
in a cellular context, we compared theChIP-seq signals over
the four classes of binding sites. FOXA1 loci with DIV sig-
natures in T47D, MCF7 and HepG2 cells exhibit signifi-
cantly stronger ChIP-seq read intensities compared to re-
gions with alternative motif matches (Figure 3C, Supple-
mentary S3C). As an alternative analysis we rankedFOXA1
ChIP-seq peaks inMCF7, T47D and HepG2 cells by signal
strength and divided them into deciles (Figure 3D). Next
we quantified the fractional occurrence of the four binding
categories per decile (Figure 3D). This analysis shows that
FOXA1/DIV peaks are concentrated in the top deciles to a
larger degree than the three other binding categories.
We also inspected ChIP-seq signals for alternative chro-
matin associated factors GATA3, the co-activator Histone
acetyltransferase P300 (EP300), CTCF and c-Jun (Supple-
mentary Figure S3E). We did not observe increased sig-
nals over DIV sequences as compared to other binding site
categories indicating that the effect is specific for FOXA1.
We conclude that FOXA1 associates with the DIV more
strongly than with monomeric or alternative dimer sites
in a chromatin context because of the highly cooperative
homodimerization promoted by this binding site. We next
performed gene ontology analysis using gene sets linked
to FOXA1/DIV binding events in T47D or MCF7 cells
with signatures of changed expression after chemical or ge-
netic perturbation (Supplementary Figure S3E). Amongst
the top most significantly enriched gene sets bound by
FOXA1/DIV are genes up-regulated in xenografts resistant
to endocrine therapy (55), differentially upregulated in lu-
minal as compared to basal or mesenchymal breast cancer
cell lines (56), down regulated in breast cancer cells depleted
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Figure 3. FOXA1 strongly binds to DIV sequences in the context of chromatin. (A) FOXA1 expression measured by the FANTOM 5 consortium in
562 cell and tissue types. Each dot represents a cell or tissue type and selected samples with highest FOXA1 expression are marked. (B) Schematic how
ChIP-seq peaks were categorized based on the absence/presence of monomer, DIV or control dimer (DIV1-10) motifs. (C) Boxplot to compare ChIP-seq
scores (ENCODE narrowPeak signal values) in the four FOXA1 ChIP-seq peak categories defined in (B) using data from T47D, HepG2 and MCF7 cells.
P-values are calculated using pairwise comparisons with the unpaired Wilcoxon rank sum test (R function pairwise.wilcox.test) and adjusted using the
Holm method (***P < 0.001). (D) ChIP-seq peaks were ranked by signal values and divided into deciles (top decile = 1, bottom decile = 10, shown as
boxplots) and the fractional counts of the four binding categories per decile are shown as proportional barplots.
of ESR1 (57) and other gene sets associated with response
to nuclear receptor signaling and oncogenic pathways. This
suggests that genes associated with FOXA1/DIV locations
are sensitive to perturbation of pathways relevant to cancer
progression in particular in breast cancer models.
FOXA1 homodimerizes on DIV motifs to regulate enhancers
near genes implicated in cancer progression
We next selected five FOXA1/DIV loci associated with
genes responsive to perturbation studies that reproducibly
showed strong ChIP-seq signals in MCF7 cells (Figure 4A,
Supplementary Figure S3E). These loci are located either
in introns or within 50 kb upstream of the TSS of genes
with a strong expression in MCF7 cells and other relevant
cell and tissue types (Supplementary Figure S4A and B).
Moreover, these genes were reported to play critical roles in
cancer or essential cellular processes including ESR1 (58),
PVT1/MYC (59), ATP9A (60), QSOX1 (61) and KAT6B
(62) (Supplementary Figure S4A). PVT1 encodes for a long
non-coding RNA that resides in the 8q24 locus shared
with the oncogene MYC (63). This locus is strongly am-
plified across a panel of malignant cancers and a marker
for poor prognosis (64,65). We performed EMSAs using se-
quence derived from these five endogenous loci as well as
two types of mutants (Figure 4B–D). First, we engineered
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Figure 4. FOXA1/DIV binding regulates gene expression in cancer cells. (A) FOXA1 ChIP-seq peaks in MCF7 cells (accession numbers indicated) at
five DIV loci near genes with potential roles in oncogenesis (see also Supplementary Figure S4A and B). (B) EMSAs using Cy5 labeled DNA elements
derived from the five endogenous DIV loci. (C) EMSAs where the five DIVDNA elements were mutated to monomer binding sites by adding a 3 base-pair
spacer destroying dimeric binding but leaving monomeric binding intact (‘Monomer’). (D) EMSA where both half sites of the DIV elements were mutated
abolishing binding (‘No binding’). (E) Homodimer cooperativity value (ω) shown as mean ± SD from n ≥ 3 measurements. (F) Total GFP fluorescence
quantified by FACS analysis using Tol2 constructs containingDIV enhancers or the two types ofmutatedDIV sites (‘Monomer’ or ‘NoBinding’) integrated
into the genomes ofMCF7 cells. FACS plots and photographs of cells are in Supplementary Figure S4D. (G) Dual Luciferase reporter assay using the T47D
cell line endogenously expressing FOXA1. (H) Dual Luciferase assay in HCT116 cells co-transfected with FOXA1 expression plasmids (filled bars) or the
pcDNA3 control (empty bars). Empty vector is the luciferase reporter without inserted DIV enhancer. Reporter signals in (F) and (G) were normalized to
‘Monomer’ values. Luciferase and Tol2 reporters were constructed as outlined in Supplementary Figure S4C. The mean± SD of three biological replicates
is shown in (F), (G) and (H). P-values were calculated using the unpaired two-tailed Student’s t-test (***P < 0.001; **P < 0.01 ;*P < 0.05).
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these loci by introducing 3 bp spacers between the half sites
reminiscent to the D3 element that is incompatible with
dimeric binding (Figure 1E, ‘Monomer’, Supplementary
Table S1). Moreover, we mutated both half-sites to generate
DNA elements with completely destroyed FOXA1 consen-
sus (‘No binding’, Supplementary Table S1). Results show
a strongly positive cooperativity for FOXA1 homodimer-
ization on all five DIV sequences with the highest  value
for the PVT1/MYC locus (Figure 4B-E). Introduction of
the 3bp spacer destroys dimeric binding but leaves the affin-
ity for monomeric binding unaffected (Figure 4C). Degen-
eration of both FOXA1 half-sites abolishes FOXA1 bind-
ing almost completely at the concentrations tested (Fig-
ure 4D). To test whether binding with purified compo-
nents is associated with gene regulation in a context of cells
and chromatin, we designed two reporter assays to validate
the enhancer activity of these loci. First, we cloned ∼500
bp fragments encompassing the FOXA1-bound DIV se-
quences tested by EMSA into Tol2 vectors. The Tol2 system
enables transposase-mediated integration into the genome
of MCF7 cells that strongly express FOXA1 (Supplemen-
tary Figure S4C). Additionally, we designed a luciferase re-
porter assay. The latter was performed in T47D cells ex-
pressing FOXA1 endogenously and in the colon cancer cell
line HCT116 where FOXA1 is not normally expressed (66)
(Supplementary Figure S4C). The expression levels of the
Tol2-GFP reporters driven by the various enhancer con-
structs were quantified in MCF7 cells using FACS and ex-
pressionwas scored taking the fraction ofGFPpositive cells
as well as the median GFP signal into account (Supple-
mentary Figure S4D). These expression levels show that se-
quences containing DIV motifs exhibit a strong enhancer
activity (Figure 4F, ‘Dimer’). The expression of GFP re-
porters where the DIV was mutated so FOXA1 can only
bind monomerically (‘Monomer’) or with two disrupted
half-sites (‘No binding’) showed a significantly depleted re-
porter activity suggesting cooperative dimerization is re-
quired for full reporter activation (Figure 4F). Analogously,
luciferase reporter activity was reduced in T47D cells for 4
out of 5 sequences when the homoderimic binding was dis-
rupted (Figure 4G). Lastly, luciferase reporter activity was
strongly elevated inHCT116 devoid of endogenous FOXA1
upon the exogenous provision of FOXA1 indicating that re-
porter activation is FOXA1-dependent (Figure 4H). Collec-
tively, these results show that FOXA1 dimerizes coopera-
tively on endogenous DNA sequences and that the dimeric
FOXA1/DIV configuration is required for the efficient ac-
tivation of these enhancer sequences.
DIV sequences mediate chromatin opening at locations pre-
bound by FOXA1 upon inhibition of the PI3K pathway
As FOXA1 is designated as a hallmark pioneer TF, we next
asked whether the FOXA1/DIV configuration is involved
in the regulation of chromatin accessibility. To address this
questionwe became interested in a study that explored chro-
matin changes in the breast cancer cell line T47D in re-
sponse to treatment with the phosphatidylinositol 3-kinase
(PI3K) inhibitor BYL719 (henceforth termed BYL) (67).
The PI3K pathway is hyperactive in∼70% of breast tumors
and therefore an attractive target for anti-cancer therapies
(68). However, PI3K kinase inhibition can lead to a potent
compensatory response and cancer relapse, presumably fa-
cilitated by ER-associated regulatory programs. To study
the molecular mechanism for this process, Toska and col-
leagues compared the binding profile of FOXA1 and the
chromatin accessibility measured by ATAC-seq in the ab-
sence and presence of BYL (67). Intriguingly, the authors
reported a motif to become enriched in the FOXA1 binding
landscape after BYL719 treatment representing a perfect
match to the DIV. However, the authors refer to this mo-
tif as ‘Homeobox’ motif because of missing annotations of
the DIV in common motif databases. We therefore decided
to probe whether FOXA1/DIV configurations contribute
to the compensatory chromatin remodeling in response to
PI3K pathway inhibition.
Peaks of the DIV category (‘D’) exhibit stronger ChIP-
seq signals than loci with monomeric sites (‘M’), sites
with perturbed dimer configurations (‘C’) and sites with-
out detectable FOXA1 consensus element (‘N’) under
both DMSO and BYL conditions (Figure 5A and B). We
grouped genomic locations according to the closed-open
dynamics measured by ATAC-seq in the absence or pres-
ence of PI3K inhibition. Permanently open (PO) sites are
open under both DMSO and BYL conditions; close-to-
open (CO) sites gain accessibility and open-to-close (OC)
sites loose accessibility in response to BYL treatment (Fig-
ure 5C). We found that majority of loci belong to the OC
category indicating lost accessibility upon BYL treatment.
However, the FOXA1 ChIP-seq signal is predominantly as-
sociated with the PO or CO categories but barely detectable
in the OC category (Figure 5C). This suggests that the ab-
sence of FOXA1 sensitizes genomic locations for closing
whilst the presence of FOXA1 could have two roles. First,
FOXA1 could function to maintain the open chromatin
state of PO sites. Second, closed sites pre-bound by FOXA1
could become open in response to PI3K inhibition. We
next inspected ATAC-seq signals over locations pre-bound
by FOXA1 under DMSO conditions. We found that lo-
cations without matches to forkhead binding motifs (‘N’)
are mostly pre-opened under DMSO conditions and show
only a marginal increase in ATAC-seq signals after BYL
treatment (Figure 5D and E, Supplementary Figure S5A).
However, strikingly, FOXA1/DIV locations pre-bound at
DMSO conditions are mostly closed but show a strong in-
crease in ATAC-seq signal following PI3K pathway inhibi-
tion (Figure 5D and E, Supplementary Figure S5A). Con-
sistently, a high proportion of FOXA1/DIV sites bound un-
der DMSO conditions maps to locations of the CO cate-
gory (Figure 5F). Whilst, FOXA1/C and FOXA1/M sites
also show a preference for CO locations this association is
more significant for FOXA1/DIV sites (Fisher’s exact test
P= 2.4e–05 (DIV versus control dimer)). We conclude that
locations pre-bound by FOXA1 under DMSO conditions
are subject to a closed-to-open transition upon PI3K in-
hibition and this effect is most profound for the subset of
FOXA1/DIV location. The PVT1/MYC and KAT6B loci
illustrate this effect with equally strongChIP-seq signals un-
der DMSO and BYL719 conditions but a strong increase
of ATAC-seq signal after PI3K inhibition (Figure 5G). We
next tested whether the DIV loci near the PVT1/MYC
and KAT6B genes respond to PI3K inhibition in our lu-
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Figure 5. FOXA1 bound DIV locations are associated with chromatin dynamics. (A, B) Boxplot of ChIP-seq scores (summit height of fragment pileup)
from FOXA1 data in T47D cells comparing peak categories for the subsets containing DIV motifs (D), control motifs (C), monomer motifs (M) and no
FOXA1motif (N) (see Figure 2B). T47D cells were exposed to DMSO (A) or to the PI3K pathway inhibitor BYL719 (B) (67). (C). Heatmap of ATAC-seq
reads as well as FOXA1 ChIP-seq reads under DMSO or BYL719 treatment conditions in three categories of accessibility patterns: PO (permanently open
in DMSO and BYL), CO (closed in DMSO but open in BYL) and OC (open in DMSO but closed in BYL). (D) ATAC-seq read heatmaps under DMSO
or BYL719 treatment conditions facetted by the four FOXA1 ChIP-seq peak categories defined in the DMSO condition. The lower panels are aggregate
pileups of ATAC-seq signals. (E) Boxplot of the ratio between ATAC-seq read counts between BYL719 treated T47D cells and non-treated (DMSO) T47D
cells in the four categories of FOXA1 binding sites. (F) Fractional barplots showing the relative proportions of FOXA1 peak categories and sites not bound
by FOXA1 (‘Unbound’) associated with PO, OC or CO sites defined according to accessibility patterns measured by ATAC-seq (see panel C). (G) Genome
browser plot examples of ChIP-seq and ATAC-seq signals at FOXA1/DIV sites near the PVT1/MYC and KAT6B loci. Black boxes mark locations with
DIVmotif while green box show alternative location showing a disappearance of ATAC-seq signals. (H) Bar plot of the Luciferase/Renilla signal measured
in T47D cells treated with DMSO (red) or BYL719 (blue) using DIV element containing luciferase reporter from the PVT1/MYC and KAT6B loci and
mutated ‘no binding’ controls. The mean ± SD of 3 biological replicates is shown. P-values in (H) were calculated using the unpaired two-tailed Student’s
t-test (***P< 0.001; **P< 0.01; *P< 0.05). P-values in (A), (B) and (E) are calculated usingWilcoxon rank sum test and adjusted using the Holmmethod
( ***P < 0.001).
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ciferase reporter assay. Sequences with intact DIV elements
show an elevated reporter activity in response to BYL treat-
ment whilst sites with mutated DIV elements show no sig-
nificant response (Figure 5H). However, plasmid-based re-
porter constructs are unlikely to exactly resemble the chro-
matin configurations of the endogenous loci. Therefore, we
cannot be certain that the observed changes to reporter
activity are due to the same chromatin closed-open dy-
namics apparent in the ATAC-seq data. Nevertheless, this
analysis suggests that of blocking the PI3K pathway leads
to chromatin remodeling at pre-bound FOXA1/DIV loca-
tions that could impact the transcriptional output.
Disease-associated SNPs within the DIV motif induce allele-
specific dimer formation and expression activity
We surmised that cooperative FOXA1 homodimerisation
on DIV sequences is necessary to execute a functional out-
come on a subset of genomic loci. If the dimer motif is
perturbed, a locus could loose the ability to effectively re-
cruit FOXA1. Or, alternatively, monomeric FOXA1 could
be unable to trigger a regulatory response despite effective
recruitment. As a consequence, aberrant cellular responses
could be evoked contributing to human diseases. To test this
hypothesis we interrogated genome-wide association stud-
ies (GWAS) for variants affecting FOXA1 dimerization.
We considered 25 218 disease-associated SNPs available
from public resources (http://www.gwascentral.org, data re-
leased January 2016) and extracted further SNPs in link-
age disequilibrium with them (proxy LD SNPs) using Hap-
loreg (http://archive.broadinstitute.org/mammals/haploreg/
haploreg.php) with parameter r2 > 0.8 in the European
population. This way, we obtained a set of 606 094 can-
didate SNPs. We then intersected SNP coordinates with
genome-wide DIV coordinates affecting the central TA site
(AAATATTT), which we assumed to be most critical for
the cooperative homodimerization of FOXA1. This way, we
obtained 23 candidate SNPs whose minor allele may per-
turb FOXA1 homodimerization and forkhead-dependent
transcriptional networks. To determinewhether FOXA1 ex-
hibits allelic differences in dimer formation, we performed
EMSAs on all 23 SNP candidates with either major or mi-
nor allele sequences. Using this strategy, we identified 15
SNPs that profoundly perturb FOXA1 dimerization (Fig-
ure 6A, Table 1, Supplementary Figure S6A). We further
inspected each of the 15 SNPs in the dataset provided by
the genotype tissue expression (GTEx) consortium (https:
//gtexportal.org/) and found that six of the SNPs or their
LD SNPs constitute GTEx expression quantitative trait lo-
cus (eQTLs, Figure 6A, Table 1). In some instances, e.g.
rs2097744 that is associated with non-small cell lung cancer,
theminor allele completely disrupted dimeric FOXA1 bind-
ing (Figure 6B). In other cases, the minor alleles decreased
the cooperativity of FOXA1 dimerization (Supplementary
Table S1). We next focused on SNPs supported by genomic
annotations in tissues relying on the activity of FOXA1 or
related forkhead family proteins.
We became particularly interested in SNP rs2941742 lo-
cated within an intron region of the ESR1 gene (Figure
6C). This SNP maps to a region with the enhancer mark
H3K27ac and the promoter mark H3K4me3 in osteoblasts,
as well as H3K27ac marks in muscle and bone marrow cells
(Figure 6C). The SNP rs2941742 is in LDwith rs2941740 (r2
= 0.98 in the European population) linked to aberrant bone
mineral density (BMD)––a trait used in the clinic to diag-
nose osteoporosis and the estimation of fracture risk (69).
Interestingly, ESR1 is a gene relevant for bone metabolism
as osteoporosis mainly affects post-menopausal women
with depressed levels of its activating ligand estrogen (70).
EMSAs showed that the minor allele reduced the homod-
imer cooperativity of FOXA1 to the rs2941742 locus 20-
fold whilst monomeric binding is not affected (Figure 6D
and E). Moreover, luciferase assays revealed reduced re-
porter activity for the minor as compared to the major al-
lele that is dependent on exogenous FOXA1 addition (Fig-
ure 6F). It is therefore conceivable that the perturbation of
FOXA1 dimers or of related forkheadTFs on the rs2941742
locus modifies ESR1 regulation and contributes to the eti-
ology of osteoporosis.
rs5414555835 (also annotated with ID rs67668514) maps
to a locus bound by FOXA1 in various cancer cell lines
(Figure 6G) and displays active histone marks in liver and
brain cells (Table 1). This SNP is in LD with rs17577094
at r2 = 0.97 in the European population and maps to the
chr17q21.31/MAPT locus (71) reported to be strongly as-
sociatedwith Parkinson’s disease (PD) (72).MAPT encodes
for the Tau protein whose de-regulation and aberrant fold-
ing is a major cause for the disease progression. Interest-
ingly, rs541455835 is a GTEx eQTL associated with al-
lele specific changes in MAPT expression in various tis-
sues (Supplementary Figure S6B). Moreover, rs541455835
shows a strong difference in binding and reporter gene ex-
pression in an allele-specific and FOXA1-dependent man-
ner (Figure 6H and I). Notably, FOXA1 and FOXA2 are
critical for the function of adult dopaminergic neurons (73).
For example, gene delivery of FOXA2 in a mouse model
for PD protected midbrain dopaminergic neurons and al-
leviated motor deficits (74). Therefore, the modulation of
FOXA1/2 dimerization on theMAPT locus could hamper
the neuroprotective roles of FOXA1/2 and contribute to
PD. Overall, we observed significant differences of reporter
expression betweenmajor andminor allele sequences for 10
of the 15 tested SNPs (Supplementary Figure S6C), five of
which are also eQTLs.
DISCUSSION
In this study, we demonstrate that FOXA1 can form a
DNA-dependent homodimer in the presence of a palin-
dromic DNA element with overlapping half-sites. Unlike
some other TFs such as SOX9 that form dimers on flexi-
bly spaced composite elements (39), FOXA1 dimerization
relies on precise half-site spacing. Interestingly, the DIV
motif was also detected, but not validated, using methyl-
SELEX with full length FOXA1 (33) and high-throughput
SELEX (32) for members of the FOXC subfamily. Further,
we noticed that in a recently reported crystal structure of
DNA bound FOXO1 an arrangement of crystallograph-
ically stacked DNA helices resembling the DIV configu-
ration (Supplementary Figure S7) (75). However, the au-
thors did not test cooperative dimer formation on such an
element. Lastly, ChIP-exonuclease sequencing studies in-
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Figure 6. Disease-associated SNPs perturb dimerization and gene expression. (A) Flowchart to select SNPs for functional evaluation. (B) EMSAs for
the rs2097744 locus where the minor allele completely disrupts dimerization. (C) ChIP-seq profiles of histone marks at the rs2941742 locus in various cell
lines. (D) EMSA comparing dimer formation for major and minor alleles of rs2941742. (E) Cooperativity factor for EMSA in D (mean ± SD, n = 5).
(F) Dual luciferase assay with exogenously supplied FOXA1 in HCT116 cells using both alleles of rs2941742 (mean ± SD, n = 5). (G) FOXA1 ChIP-seq
profiles from several human cancer cell lines at the rs5414555835 locus (an alternative ID of the same locus is rs67668514). (H) EMSAs using the major
and the minor allele of rs5414555835. I. Dual luciferase assay for the two alleles of the rs5414555835 locus in HCT116 cells. Filled bars are for exogenously
provided full length FOXA1 and empty bars for the pcDNA3 vector controls (mean ± SD, n = 3 biological replicates). P-values were calculated using the
unpaired two-tailed Student’s t-test (**P < 0.01).
dicated the presence of various forms of composite fork-
head elements. First, two clustered forkhead sites (termed
mesas) resembling a widely spaced CON element (Figure
1A) were reported (31). Second, a DIV signature was seen
in glucocorticoid receptor (GR)ChIP-exo data showing sig-
natures of cooperative binding and implying roles of the
DIV for GR recruitment to chromatin (30). Collectively,
the DIV motif could be a broadly used forkhead recog-
nition sequence relevant for TFs beyond FOXA1. As a
consequence, the dimer-modifying GWAS SNPs reported
here could elicit their phenotypic consequence by perturb-
ing regulatory programs of any forkhead protein. SNPs
rs2941742 and rs541455835 are the most interesting can-
didates for a forkhead associated disease mechanism. They
localize to distal enhancer of ESR1 and MAPT genes,
which are related to osteoporosis or Parkinson’s disease, re-
spectively. The rs2941742[G] osteoporosis risk allele leads
to a near 100-fold decrease in FOXA1 homodimer coop-
erativity, and causes depressed reporter gene expression.
Whilst FOXA1, to our knowledge, has not been impli-
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Table 1.
SNP ID Location (hg38) Gene Disease association Annotation Luciferase GTEx
Major Minor eQTL
rs2858870 chr6:32604474 HLA-DRB1 Nodular sclerosis Hodgkin
lymphoma
Promoter histone marks,
enhancer histone marks, and
DNase marker of
lymphoblastoid Cells, blood
and mucle cells
− − N
rs2097744 chr7:118382988 LSM8,
ANKRD7
Response to platinum-based
chemotherapy in
non-small-cell lung cancer
++ ++ Y
rs767441 chr15:48613619 FBN1 Breast cancer Promoter histone marks and
enhancer histone marks of
adipocyte, muscle and lung cells
− − N
rs2104047 chr14:68287700 RAD51B Primary biliary cirrhosis Promoter histone marks and
enhancer histone marks of
blood cells, muscle cells, thymus
and hematopoietic stem cells
++ ++ N
rs2941742 chr6:151691853 ESR1 Bone mineral density (hip) Promoter histone marks and
enhancer histone marks of
osteoblast cells, muscle cells,
blood cells and liver cells
++ + N
rs541455835
(rs67668514*)
chr17:46099939 KANSL1,
MAPT
Parkinson’s disease Promoter histone marks and
enhancer histone marks of
brain cells, liver cells and blood
cells
++ +++ Y
rs281038 chr5:156653467 SGCD Anthropometric traits Enhancer histone marks of
foreskin melanocyte primary
cells
+ − Y (rs157350)
rs6990531 chr8:80483511 ZBTB10 Eating disorders Promoter histone marks and
enhancer histone marks of
brain, muscle and blood cells
+ ++ N
rs7697634 chr4:17965123 LCORL Height Promoter histone mark of liver
and enhancer histone mark of
pancreatic islets
++ + Y
rs7957274 chr12:21197462 SLCO1B1 blood metabolite
measurement
Promoter histone marks and
enhancer histone marks of ESC
and blood cells
+ ++ N
rs11716984 chr3:121643560 HCLS1 neuropsychological test Promoter histone marks and
enhancer histone marks of
ESC, iPSC and blood cells
++ − Y
rs62288111 chr3:190946175 SNAR-I,
GMNC
Alzheimers disease Promoter histone mark of adult
liver tissue and enhancer
histone mark of hESC Derived
CD56+ ectoderm cultured cells
+ ++ N
rs34466261 chr7:104835293 LHFPL3 Obesity Enhancer histone mark of
HUES48 ESC cells
+ − N
rs2149943 chr10:107811551 SORCS1 Prion diseases Enhancer histone mark of
ES-UCSF4 cells and pancreatic
islets
++ + N
rs7007731 chr8:76783496 ZFHX4 age at menarche Enhancer histone mark of
Mesenchymal cells
− ++ Y
(rs4735738)
15 SNPs that show allelic differences in the homodimeric binding of FOXA1 to sites with DIV motifs. ‘+’ indicates luciferase expression level increased comparing to empty
vector and ‘–’ that it decreased. denotes a previously used alternative
SNP ID
cated in osteoporosis, the FOXO group plays an impor-
tant role in bone metabolism by regulating the redox bal-
ance, protein synthesis and differentiation in the osteoblast
lineage (reviewed in (76)). Similarly, rs541455835 risk al-
leles promote modulation in gene expression through per-
turbation of FOXA1 homodimerisation. Several studies
found that the original GWAS SNPs linked to the dimer
modifying SNPs (rs2941740 for rs2941742; rs17577094 for
rs67668514) were associated with eQTLs (77,78). Impor-
tantly, rs17577094 not only affects MAPT gene expression
in the brain, but also in other tissues including the breast
where the rs67668514 locus shows strong FOXA1 ChIP-
seq signals. We also found that rs767441[C], which is one of
the breast cancer risk-associated SNPs reported byCowper-
Sallari et al (26), destroyed dimeric binding without chang-
ing the affinity for monomeric binding. Genome editing
studies provide the means to test whether perturbing fork-
head DBD dimerization on disease-associated loci influ-
ences disease progression. Collectively, the identification of
disease associated SNPs at regulatory genomic regions that
reduce FOXA1 dimerization and perturb reporter gene ex-
pression corroborates our hypothesis that FOXA1 dimer-
ization is critical for its regulatory function and contributes
to disease progression.
While we showed that FOXA1/DIV configurations are
linked to highly expressed genes, these binding events do not
appear to act as simple transcriptional amplifier. Accord-
ingly, the effects of minor alleles of the studied SNPs are
diverse. Reporter assays showed that the presence of minor
alleles could lead to elevated, reduced or unchanged expres-
sion levels relatively to major alleles (Figure 6E, F and I).
Likewise, when the expression of eQTLs is compared across
tissues, the minor allele can be associated with increased
expression levels in one tissue but with reduced expression
levels in another (Supplementary Figure S6B). This impli-
cates that regulatory outcomes of FOXA1/DIV complexes
are dependent on the overall sequence as well as the cellu-
lar context. For example, whether a FOXA1/DIV complex
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recruits co-activators or repressors could be influenced by
peripheral sequences and change from one cell to another.
The association of DIV sequences with open-close dynam-
ics of chromatin suggests a role of FOXA1/DIV complex in
chromatin remodeling. An important question is whether
the regulatory consequence of FOXA1 dimers on DIV mo-
tifs is different than other configurations such asmonomers,
heterodimers or homodimers on CON sequences. Clearly,
we identified enhancers that rely on FOXA1/DIV dimers
for their activity. An intriguing possibility is that the DIV
motif not only affects the strength and dynamics of bind-
ing but also has qualitative effects. A possible mechanism
is that only when bound to DIV sequences FOXA1 would
recruit a set of co-factors that in turn may trigger trans-
activation, chromatin looping or the setting of epigenetic
marks in a cell type dependent manner. By contrast, alter-
native FOXA1 configurations induced by other DNA mo-
tifs could lead to disparate nuclear processes. Such a mech-
anism could explain the context specific activities of mas-
ter TFs such as FOXA1 allowing them to regulate different
sets of genes in a multitude of cells and at different devel-
opment stages. Collectively, homodimeric FOXA1 critically
contributes to its genomic binding landscape and its regula-
tory activity, likely by influencing chromatin dynamics and
by modulating its interactome.
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